Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B. Corcoran, Geoffrey I. Shapiro, Jeong Eun Kim et al.|Clinical Cancer Research|2024Cited by 39